Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation
- 17 March 2005
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 19 (5) , 814-821
Abstract
Both conventional chimerism analysis (CCA) and lineage-specific chimerism analysis (LCA) have potential pitfalls as diagnostic means for the detection of minimal residual disease after allogeneic hematopoietic cell transplantation (aHCT). Therefore, the present study examines the results of both methods in order to determine how predictive consecutive evaluations were, with respect to the risk that the patient would relapse during post-transplant follow-up and with respect to responsiveness to immunomodulatory treatment. A total of 168 individuals with acute myeloid leukemia (AML) (n=137) and myelo dysplastic syndrome (n=31) were investigated with CCA and LCA at mean intervals of 24 days (range: 11–116). The median follow-up after myeloablative aHCT was 22 months (range: 4–49). Of 168 patients, 65 experienced a clinical relapse after aHCT. CCA and LCA were comparatively sensitive and specific for relapse at the intervals of chimerism testing employed in this study. Of 32 patients, 10 who were offered donor lymphocyte infusions (DLI) treatment for increasing (n=29) or stable (n=3) mixed chimerism (MC) achieved at least transitory CC. The observation that all patients with increasing MC relapsed despite DLI treatment (54%) or withdrawal of immune suppression (24%) indicates that novel strategies to deal with rapidly evolving relapse in AML patients, such as shortening of chimerism monitoring intervals, need to be evaluated.Keywords
This publication has 35 references indexed in Scilit:
- Prognostic Value of Minimal Residual Disease Quantification by Real-Time Reverse Transcriptase Polymerase Chain Reaction in Patients With Core Binding Factor LeukemiasJournal of Clinical Oncology, 2003
- Donor leukocyte infusions for multiple myelomaBone Marrow Transplantation, 2000
- Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantationBone Marrow Transplantation, 2000
- Mixed chimerism in the B cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B cell acute lymphoblastic leukemiaBone Marrow Transplantation, 2000
- Donor Leukocyte Transfusions for Treatment of Leukemic Relapse after Bone Marrow TransplantationVox Sanguinis, 1998
- Detection of CBFβ/MYH11 fusion transcripts in patients with inv(16) acute myeloid leukemia after allogeneic bone marrow or peripheral blood progenitor cell transplantationBone Marrow Transplantation, 1998
- Flow cytometric cell sorting combined with molecular chimerism analysis to detect minimal recurrent leukemia: good news and bad newsBone Marrow Transplantation, 1997
- Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effectBone Marrow Transplantation, 1997
- The presence of lymphoid‐associated antigens in adult acute myeloid leukemia is devoid of prognostic relevanceStem Cells, 1995
- Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groupsGenomics, 1992